How effective is Rituximab in treating rheumatoid arthritis?

Rituximab is a monoclonal antibody that works by targeting the CD20 protein antigen displayed on the B cell surface. It is used to treat rheumatoid arthritis and many other conditions, including non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL), granulomatosis with polyangiitis (GAP), and moderate to severe pemphigus. Rituximab in combination with methotrexate is used in adult patients with moderately to severely active rheumatoid arthritis who have not responded to treatment with one or more TNF (tumor necrosis factor) antagonists. Clinical trial results show that rituximab treatment successfully improves patient outcomes, including reducing symptoms, fatigue and disability, and improving health-related quality of life. It also slows down the progression of structural damage to joints.

Rituximab combined with methotrexate is better than methotrexate alone in improving symptoms. In clinical trials, the ACR (American College of Rheumatology) response criteria measure how much a patient's symptoms improve between two set time points. Common ones are ACR20, ACR50 and ACR70. Between two set time points, ACR20, ACR50 and ACR70 patients' symptoms improved by ≥20%, ≥50% and ≥70% respectively. ACRThe standards look at the amount of swelling and pain in a patient's joints, creactive protein levels, erythrocyte sedimentation rate and other measures of pain, disability and disease activity. IIIPhase REFLEX (randomized evaluation of rituximab in RA(51% vs 18%),ACR 50 (27% va 5%) and ACR 70 (12% vs The proportion of 1%) increased significantly (p<0.0001). Patients enrolled in the trial had active, long-standing rheumatoid arthritis and an inadequate response to treatment with anti-tumor necrosis factor drugs. The European League Against Rheumatism (EULAR) response criteria also showed that 65%of patients treated with rituximab plus methotrexate achieved a moderate to good EULAR response compared with placebo Only 22% of patients treated with methotrexate achieved a moderate to good EULAR response (p<0.0001). Another phase III trial called SUNRISE also showed that patients who received a second course of rituximab (re-treatment) were better than placebo plus methotrexate.

Improving fatigue, disability, and health-related quality of life with rituximab treatment. The REFLEX trial also used the FACIT-F, HAQ·Dihe SF-36 scores to measure the efficacy of rituximab. The results showed that treatment with rituximab plus methotrexate was better than placebo plus methotrexate in improving fatigue, disability, and health-related quality of life. Rituximab-treated patients had significantly lower levels of fatigue, as measured by the FACIT-F (Functional Assessment of Chronic Illness Treatment-Fatigue) scale. Their scores dropped an average of 9.1 points, indicating a 29.6% improvement in their fatigue levels, while patients who did not receive Rituxan only dropped 0.5 points. 6%of patients receiving rituximab had HAQ at 24weeks The DIscore was 0 compared with 0.5% in patients who did not receive rituximab. The Health Assessment Questionnaire Disability Index is a questionnaire used to determine a patient's functional abilities, including their ability to dress, eat, walk, reach, care for themselves, etc. According to SF-36 (one item includes 36Patients treated with rituximab experienced significant improvements in both mental and physical health, as measured by a brief survey. Mental and physical health domain scores increased by 4.7 and 5.8 points, respectively, among patients who received rituximab plus methotrexate compared with those who did not receive rituximab Treated patients gained only 1.3 and 0.9 points, respectively (p=0.0002). If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.